BiVictriX’s preclinical data supports progression into human trials
BVX001 extended survival rates when compared to HiDAC, a potent but highly toxic AML chemotherapy drug, as well as an untreated control group.
It found that a 28-day dosing period, BVX001 (dosed at 10mg/kg twice weekly) delivered a median survival of 129 days, in contrast to 91 days for HiDAC and 57 days for the untreated control. BVX001 showed a 126% median survival advantage over the untreated control and a 42% advantage over HiDAC, representing a huge improvement in AML treatment.
This preclinical model underlines BVX001's potential against AML by addressing a greater number of cells driving cancer progression. These results build upon previous positive preclinical murine efficacy data, making BVX001 a promising candidate for the next generation of precision AML therapies.
Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, said: “We are greatly encouraged by this recent pre-clinical data, demonstrating that BVX001 provides clear survival benefits, even in this challenging AML model. This data adds further strength to our existing and comprehensive pre-clinical data package, as we accelerate work towards obtaining regulatory approval to support the progression of BVX001 into human trials."
View from Vox
BiVictriX remains well positioned in one of the fastest-growing markets in oncology, with the news today taking the company one step closer to eventually commercialising its game-changing cancer treatment. The global precision oncology market size was valued at US$100.06 billion in 2022 and is projected to surpass US$258.35 billion by 2032, with the therapeutics segment contributing the largest revenue share of 72% in 2022.
BiVictriX’s success is underpinned by its Bi-Cygni® therapeutics technology, which identifies cancer-specific ‘fingerprints’- novel combinations of antigens that are co-expressed on cancer cells but largely absent on healthy cells.
Benefits offered by Bi-Cygni® therapeutics include significantly reduced toxicity enabling higher dosing and greater efficacy, with this reduced toxicity expanding options for combinatorial therapies. Combinatorial therapies decrease the chance a tumor will be resistant to the treatment.
BiVictriX is in an exciting position, now moving swiftly towards regulatory approval to support the progression of BVX001 into human trials, and one step closer to bringing its cutting-edge cancer treatment to patients.
Follow BiVictriX for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.